BroadOak Capital Partners Announces Multiple Growth Investments

BroadOak Fund VI completes first investment in Azure Biosystems; additional investments in Codis, VIDA Diagnostics, and Prognos Health

BETHESDA, Md.--(BUSINESS WIRE)-- BroadOak Capital Partners (“BroadOak”), a life-sciences focused investment and advisory firm, today announced multiple growth investments across its platform, highlighted by the first investment from BroadOak Fund VI, a growth equity financing in Azure Biosystems. This marks the third time over two decades that BroadOak has successfully partnered with the founders of Azure.

BroadOak also formed and capitalized a special purpose vehicle to support Codis (formerly Particle Dynamics) in completing its acquisition of EUROAPI’s Haverhill site. The firm’s list of portfolio companies grew with recent investments into VIDA Diagnostics and Prognos Health. “BroadOak’s partnership enables us to expand our platform’s reach and deliver even greater insights to life sciences organizations striving to improve patient outcomes,” Sundeep Bhan, CEO of Prognos Health.

“We are happy to report continued investment into the companies that are improving the way life sciences research is conducted and how the resulting breakthroughs are delivered to market,” said Bill Snider, Partner at BroadOak.

The recent expansion of BroadOak’s capital base has enhanced the firm’s ability to be a long-term partner to emerging leaders across the life sciences ecosystem. Last month, BroadOak announced more than $200 million of permanent capital to supplement its multi-vehicle investment platform, providing greater flexibility across market cycles.

About BroadOak Capital Partners

BroadOak Capital Partners is a life-sciences-focused boutique financial institution providing direct investment and investment banking services to companies in research tools and consumables, diagnostics, and biopharma services. BroadOak has led or participated in over 75 investments and has advised on more than 50 M&A transactions. In October 2025, the firm added over $200 million of permanent capital to further supplement its investment platform.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251112634584/en/

Media Contact
Andrew Moore
[email protected]

Source: BroadOak Capital Partners

You May Also Be Interested In

• Sangfor aSV Now Supported by Veeam Backup & Replication 13.1
• Faraday Future Founder and Global CEO YT Jia Shares Weekly Investor Update: Renewed Nasdaq Compliance, “Built in USA” Upgrades Including the Launch of Universal Beyond-Line-of-Sight Teleoperation
• Second PIC/S GMP Certification | Mabwell Passes Brazilian GMP Inspection for Its Denosumab Injections